Meet the Proteona Team in Nanjing, China
Innovative combined genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
The Proteona team will be presenting two scientific talks in Nanjing in June 2019.
Dr Jonathan Scolnick and Dr Andreas Schmidt will meet with immunotherapy experts from the Nanjing Medical University on the 17th June, and discuss the application of Proteona’s ESCAPETM RNA sequencing platform in analysing cancer immunology and immunotherapy samples. On the 25th June, Dr Scolnick is invited to speak at the First Purple Mountain International Health Conference and Jiangbei New Area Precision Medicine Forum, where he will share about the importance of single-cell proteogenomic analysis for cell therapies.
Since the establishment of the Nanjing Biotech and Pharmaceutical Valley in 2011, Nanjing has attracted hundreds of local and international companies, forming a strong ecosystem for new drug development, clinical testing, and manufacturing. Do schedule a meeting with the Proteona team if you happen to be in the region.
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).